Hello, page-4

Telix at the ANTSNM 2023May 25, 2023Join Telix in Adelaide, South Australia, for the 53rd annual scientific meeting of the Australian and New Zealand Society of Nuclear Medicine from May 26 to 28.We are pleased to support the first nuclear medicine event in Australia with a range of Telix experimental assets presented in presentations throughout the weekend.Our team will be at booths 13 and 15 to learn more about our PSMA-PET approved imaging agent for prostate cancer and the diagnostic and therapeutic solutions we are developing as part of our industry-leading therapeutic pipeline.The details of the ANZSNM presentation are as follows (every ACST hours):Conversation by the fireside with Associate Professor Brian Shuch MDDate and time: Friday, May 26, 7:30 p.m.Title: Molecular biopsy? New frontiers of ImmunoPET imaging in renal cell carcinomaSign up hereOral presentations?Date and time: Saturday, May 27, 3:00 pm - 3:15 pmTitle: 89 Zr-DFO-girentuximab for PET/CT imaging of clear cell carcinoma of the kidney - results of the ZIRCON phase III studyPresenter: Prof. Andrew Scott AM (Austin)Date and time: Saturday, May 27, 1:45 p.m. - 2:00 p.m.Title: The addition of peposertib, a DNA-dependent protein kinase inhibitor (DNA-PK), improves the effectiveness of 177 Lu-based radioimmunotherapy in preclinical models of prostate and kidney cell cancerPresenter: Prof. Andrew Scott AM (Austin)Poster presentations.Title: A multicentre evaluation of the 177 Lu SPECT/CT calibration process for the ProstACT TARGET studyPresenter: Quan Boon Lee, PhD (GenesisCare)Title: External radiotherapy with theranostic radioligand for oligometastatic prostate cancer (ProstACT TARGET)Presenter: Prof. Nat Lenzo, MD (GenesisCare)Title: Safety, Biodistribution and Dosismetry Study 177 Lu-TLX591 (ProstACT SELECT)Presenter: Shams Arifeen, TelixTitle: Are monoclonal antibodies suitable for targeted radiation therapy using alpha emitters?Presenter: Divesh Kumar, TelixTitle: APOMAB® as a theranostic tool in the treatment of cancerPresenter: Alex Staudacher, PhD (University of Adelaide)Title: Manufacture of [89 Zr]-DFOSq-APOMAB® for the first human clinical trialPresenter Hiu Lam, PhD (University of Adelaide)

try Google translate!